These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 227299)

  • 21. Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex.
    Ha S; Li F; Troutman MC; Freed DC; Tang A; Loughney JW; Wang D; Wang IM; Vlasak J; Nickle DC; Rustandi RR; Hamm M; DePhillips PA; Zhang N; McLellan JS; Zhu H; Adler SP; McVoy MA; An Z; Fu TM
    J Virol; 2017 Apr; 91(7):. PubMed ID: 28077654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determinants of the source of cytomegalovirus in murine renal allograft recipients.
    Klotman ME; Henry SC; Hamilton JD
    Transplantation; 1987 Nov; 44(5):636-9. PubMed ID: 2825382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Kharfan-Dabaja MA; Boeckh M; Wilck MB; Langston AA; Chu AH; Wloch MK; Guterwill DF; Smith LR; Rolland AP; Kenney RT
    Lancet Infect Dis; 2012 Apr; 12(4):290-9. PubMed ID: 22237175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytomegalovirus vaccine virus (Towne strain) does not induce latency.
    Plotkin SA; Huang ES
    J Infect Dis; 1985 Aug; 152(2):395-7. PubMed ID: 2993436
    [No Abstract]   [Full Text] [Related]  

  • 25. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
    Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
    Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytomegalovirus vaccines: current status.
    Starr SE
    Infect Agents Dis; 1992 Jun; 1(3):146-8. PubMed ID: 1365538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge.
    Plotkin SA; Starr SE; Friedman HM; Gönczöl E; Weibel RE
    J Infect Dis; 1989 May; 159(5):860-5. PubMed ID: 2540247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytomegalovirus (CMV) in the compromised host(s).
    Betts RF; Hanshaw JB
    Annu Rev Med; 1977; 28():103-10. PubMed ID: 193429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of morbidity and mortality of wild murine cytomegalovirus by vaccination with attenuated cytomegalovirus.
    Howard RJ; Balfour HH
    Proc Soc Exp Biol Med; 1977 Nov; 156(2):365-8. PubMed ID: 200952
    [No Abstract]   [Full Text] [Related]  

  • 30. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection.
    Lilleri D; Fornara C; Chiesa A; Caldera D; Alessandrino EP; Gerna G
    Haematologica; 2008 Feb; 93(2):248-56. PubMed ID: 18245650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccination against human cytomegalovirus with live virus.
    Plotkin SA; Friedman HM; Starr S; Fleisher G
    Dev Biol Stand; 1982; 52():373-9. PubMed ID: 6299846
    [No Abstract]   [Full Text] [Related]  

  • 32. Prevention of cytomegalovirus disease in transplant recipients.
    Pidgeon GB; Bailey RR
    N Z Med J; 1993 Nov; 106(967):468-9. PubMed ID: 8233192
    [No Abstract]   [Full Text] [Related]  

  • 33. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
    Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
    J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The immunological underpinnings of vaccinations to prevent cytomegalovirus disease.
    McCormick AL; Mocarski ES
    Cell Mol Immunol; 2015 Mar; 12(2):170-9. PubMed ID: 25544503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytomegalovirus infection in patients with solid-organ transplant. Recently reviewed immunologic response and pathogenicity mechanisms.
    Caltenco-Serrano R; Sánchez-Huerta JL; Vargas-Jiménez R; Rodríguez-Suárez RS; Gómez-Barreto D
    Rev Latinoam Microbiol; 2001; 43(4):177-82. PubMed ID: 17061506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytomegalovirus infection in transplant patients.
    Betts RF
    Prog Med Virol; 1982; 28():44-64. PubMed ID: 6283602
    [No Abstract]   [Full Text] [Related]  

  • 37. Cellular immune response to cytomegalovirus infection after renal transplantation.
    Linnemann CC; Kauffman CA; First MR; Schiff GM; Phair JP
    Infect Immun; 1978 Oct; 22(1):176-80. PubMed ID: 215541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
    Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
    Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical validation of a novel enzyme-linked immunosorbent spot assay-based in vitro diagnostic assay to monitor cytomegalovirus-specific cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study.
    Banas B; Steubl D; Renders L; Chittka D; Banas MC; Wekerle T; Koch M; Witzke O; Mühlfeld A; Sommerer C; Habicht A; Hugo C; Hünig T; Lindemann M; Schmidt T; Rascle A; Barabas S; Deml L; Wagner R; Krämer BK; Krüger B
    Transpl Int; 2018 Apr; 31(4):436-450. PubMed ID: 29284181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinetic of the CMV-specific T-cell immune response and CMV infection in CMV-seropositive kidney transplant recipients receiving rabbit anti-thymocyte globulin induction therapy: A pilot study.
    Martín-Gandul C; Pérez-Romero P; Mena-Romo D; Molina-Ortega A; González-Roncero FM; Suñer M; Bernal G; Cordero E;
    Transpl Infect Dis; 2018 Jun; 20(3):e12883. PubMed ID: 29570917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.